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Background: Medication for Chronic Obstructive Pulmonary Disease (COPD) has shown to sub-
stantially reduce symptoms and slow progression of disease. However, non-adherence to medi-
cation is common and associated with worsened clinical and economic outcomes.
Objective: The objective of this study was to perform a systematic review of published liter-
ature to assess the impact of non-adherence to COPD medication on clinical and economic out-
comes.
Methods: A search in PubMed and Web of Science databases was conducted of original studies
published from database inception to 2012. Studies must report on the association between
adherence to COPD medication and outcomes, published in English in peer-reviewed journals
and full texts needed to be available.
Results: Twelve full articles were included in the review. Most studies were retrospective data-
base studies. Seven studies reported on the association between adherence and clinical out-
comes, two on mortality, three on costs, four on quality of life and one on work
productivity. Results indicated a clear association between adherence and both clinical and
economic outcomes. Evidence from studies revealed increased hospitalizations, mortality,
quality of life and loss of productivity among non-adherent patients.) 50 3638204; fax: þ31 (0) 50 3632772.
ug.nl (J.F.M. van Boven).
3 Elsevier Ltd. All rights reserved.
3.08.044
104 J.F.M. van Boven et al.Conclusion: This review revealed a clear association between non-adherence to COPD medica-
tion and worsened clinical and economic outcomes making non-adherent patients a priority for
cost-effective interventions.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Medication for patients with Chronic Obstructive Pulmonary
Disease (COPD) has demonstrated to improve disease
symptoms and to avoid exacerbations [1,2]. However, ef-
ficacy reported in clinical trials may not reflect effective-
ness in a real-world setting, and one of the major reasons is
related to treatment adherence. Adherence (synonym:
compliance) is defined as the extent to which a patient acts
in accordance with the prescribed interval and dose of a
dosing regimen [3]. While therapy adherence in clinical
trials is often relatively high, adherence to COPD medica-
tion in real world settings is far from optimal [4]. Factors
associated with non-adherence to COPD medication include
dosing regimen, comorbidity, age and cost [5e7].
Non-adherence in general has been linked to preventable
morbidity and mortality and increased healthcare costs and
productivity losses [8e10]. However, the clinical and eco-
nomic consequences of non-adherence in COPD are not yet
fully understood [11,12]. The objective of this study was to
perform a systematic review of the literature assessing the
clinical and economic impact of non-adherence in COPD.
Methods
Review strategy
Literature searches were performed in February 2013 in the
PubMed and Web of Science (ISI) databases including
studies from database inception to 2012. Studies needed to
measure patients’ adherence to COPD medication and its
impact on clinical and/or economic outcomes. Search
terms were combinations of disease-, medication-, adher-
ence- and outcome terms. A specification of the review
protocol is provided in Appendix 1.
Studies found were independently screened and under-
went a quality assessment by two reviewers (JFMvB and
SV). No major disagreement between the two reviewers
occurred. A PRISMA flow diagram is provided in Fig. 1 [13].
Eligibility
To be included, studies needed to meet the following in-
clusion criteria:
(i) published in peer-reviewed journals, (ii) full text (i.e.
no abstracts), (iii) in English (iv) and reflecting an original
study. Non-English studies were not included as these tend
to be smaller and of lower methodological quality [14].
Exclusion criteria
We excluded: (i) studies assessing physician or patient
adherence to guidelines, programs or oxygen (ii) studiesincluding primarily asthma patients (iii) reviews, com-
ments, conference abstracts, case reports or editorials (iv)
animal studies and (v) studies reporting no clinical or eco-
nomic outcomes.
Data extraction
The following information was extracted for each study: (i)
first author, country and year of publication, (ii) population
characteristics (size, % male, mean age and FEV1%pred),
(iii) medication assessed, (iv) method of measuring and
defining adherence, (v) an outcomes summary (vi) absolute
and relative outcomes including p-values.
Quality assessment
The Strengthening the Reporting of Observational Studies
in Epidemiology (STROBE) checklist was used as the tool
for quality assessment of the included observational
studies [15]. This checklist, containing 22 items, was
operationalized into a series of questions for each study
design, answered by “yes”, “partly”, “no” or “not appli-
cable”. For each study, the proportion of adequately re-
ported items (“yes”) from all applicable items was
analyzed (Appendix 2).
Results
Study selection
A search in PubMed and Web of Science yielded 3410 arti-
cles in total. Removing duplicates and screening of titles
and abstracts identified 138 articles potentially relevant
articles. After review of the full texts, twelve articles
meeting the inclusion criteria remained. Results of the se-
lection process are presented in Fig. 1. Details of search
results are provided in Appendix 1. The quality assessment
is presented in Appendix 2.
Overview of included studies
After exclusion of non-relevant studies, twelve studies
remained that focused on the impact of non-adherence
with COPD medication on costs and clinical effects. The
measured outcomes varied from clinical symptoms like
cough and dyspnea to mortality and costs (Table 1). Most
studies were retrospective database studies and had an
average follow-up of one to two years. Two studies were
cross-sectional analyses [16,17]. Population size varied
between 24 [18] and 55,076 patients [19]. Most studies re-
ported clinical outcomes; only three studies reported costs
[17,19,20] and one study reported on the association be-
tween adherence and work productivity [16].
Figure 1 Selection process of the studies included in the review.
Adherence to COPD medication and outcomes 105To measure adherence, most studies [16,17,19e21] used
administrative or prescription databases. If a threshold was
used to separate adherent patients from non-adherent
patients, adherence was defined as 80% of the proportion
of days covered (PDC) in the majority of studies
[16,17,20,22].
Clinical outcomes
Seven studies explored the impact of non-adherence on
clinical outcomes, with a primary focus on hospitalizations.
Two studies reported significantly fewer hospitalizations in
adherent patients [17,22].
The Simoni-Wastila et al. study was a retrospective
cross-sectional study, included 33,816 COPD patients iden-
tified from an administrative database and had a maximum
follow-up of 1.5 years. Both medication continuity (persis-
tence) and proportion of days covered (PDC) was assessed
and patients with a PDC 0.80 were considered adherent.
In adherent and continuing patients significant lower
hospitalization rates were observed. The second study, by
Vestbo et al., was a post-hoc analysis of the large multi-
national TORCH trial in which 6112 COPD patients were
followed for 3 years [2]. Good adherence was defined as
>80% use of study medication, counted by a dose counter
on the inhaler device. Results showed that good adherence
was significantly associated with a lower rate of severe
exacerbations, independent of study treatment.One study found a non-significant association between
adherence and fewer hospital days [23]. In this 1-year
prospective cohort study (by Turner et al.) 985 COPD pa-
tients were stratified in two adherence groups based on
average number of minutes using nebulizer therapy. The
median observed time of 25 min was used as cut-off for
being adherent or not. For this study, the lack of signifi-
cance may be explained by the use of this nonconventional
method of defining adherence.
In contrast, one study found no difference in non-
adherence between hospitalized and non-hospitalized pa-
tients [24]. This study, by Matuszewski et al., used a case-
control design. The population included 93 patients hospi-
talized for exacerbation of COPD and 93 control patients
with COPD who were non-hospitalized. Non-compliance was
calculated by dividing the number of days without medi-
cation by the total days of medication prescribed during the
study (365 days). Results showed no significant difference
in mean non-compliance ratio. However, results may be
prone to bias as there was a significant difference in the
number of medications used between cases and controls
which is not only affecting adherence but is also a surrogate
indicator of disease severity, implicating that if patients
experience a hospitalization those are generally the more
sicker group. Therefore, the value of using a case-control
design for this purpose can be questioned.
Two studies found a significant association between
adherence and emergency department (ED) visits [19,21].
Table 1 Characteristics of studies reporting outcomes associated with adherence to COPD therapy.
Study (1st
author,
country, year)
Study design
(follow-up)
Population Medication Adherence
definition
Reported outcomes associated with adherence Study
quality
(STROBE)
Clinical
outcomes
Mortality Costs Quality
of
life
Productivity
Dompeling (Netherlands,
1992) [18]
Prospective
intervention (1
year)
N Z 24
Mean age: 55
Male: 58%
FEV1%pred: 63
Beclomethasone
dipropionate
400 mg plus
salbutamol or
ipratropium
PDC 80e120 X 17/28
Turner (US/
Canada,
1995) [23]
Prospective
cohort (1 year)
N Z 985
Mean age: 61
Male: 81%
FEV1%pred: 41
Metaproterenol or
other
bronchodilators
[all by nebulizer]
>25 min per
day use of
nebulizer
X X X 18/26
Corden (UK,
1997) [26]
Prospective
cohort (4 weeks)
N Z 82
(74% COPD)
Mean age: 65
Male: 54%
FEV1%pred: NA
SABA, LABA, SAAC
or corticosteroids
[all by nebulizer]
PDC, no
threshold
X 20/29
Matuszewski
(US, 1999)
[24]
Retrospective
case control (1
year)
N Z 186
Mean age: 70
Male: 98%
FEV1%pred: NA
SAAC, LAAC, SABA,
LABA, ICS, XAN
PDC, no
threshold
X 19/28
Vestbo
(Worldwide,
2009) [22]
Post-hoc
analysis
of RCT
(3 years)
N Z 6112
Mean age: 65
Male: 76%
FEV1%pred: 44
Placebo, SAL, FLU,
Combination
(SAL þ FLU)
PDC > 80 X X 28/32
Halpern (US,
2011) [20]
Retrospective
database
analysis (1.5
years)
N Z 4537
Mean age: 61
Male: 53%
FEV1%pred: NA
TIO or SAL þ FLU MPR  80 X 26/30
Agh (Hungary,
2011) [28]
Observational
cross sectional
N Z 170
Mean age: 64
Male: 42%
FEV1%pred: NA
SABA, LABA, SAAC,
LAAC, ICS,
combinations
MMAS score
3
X 17/30
Butler (US,
2011) [21]
Retrospective
longitudinal
database
(3 years)
N Z 24,138/
3231
Mean age: 66
Male: 35%
FEV1%pred:NA
Not specified Non-
adherent
days/total
days, no
threshold
X 17/28
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Takemura
(Japan, 2011)
[25]
Cross sectional
questionnaire
N Z 55
Mean age: 69
Male: 73%
FEV1%pred: 68
LAMA, LABA,
SABA, ICS
Self-report
questionnaire
score >4
X 17/29
Toy (US, 2011)
[19]
Retrospective
database
(1 year)
N Z 55,076
Mean age: 69
Male: 43e53%
FEV1%pred:NA
SAAC, LABA, LAAC PDC, no
threshold
X X 21/28
Carls (US, 2012)
[16]
Retrospective
cross sectional
(1 year)
N Z 20,985
Mean age:
46e52
Male: 54%
FEV1%pred: NA
ICS, LEU, mast cell
stabilizers, XAN,
LAMA/SAMA,
LABA, CORT
PDC >80 X 26/30
Simoni-Wastila
(US, 2012)
[17]
Retrospective
cross sectional
(1.5 year)
N Z 33,816
Mean age: 71
Male: 35%
FEV1%pred: NA
ICS, ICS þ LABA,
SAAC, LAAC, XAN
Continuation:
No gap >3
months
Adherent:
PDC  80
X X 26/30
FLU: fluticasone, ICS: inhaled corticosteroids, LABA: long-acting beta agonists, LAAC: long acting anticholinergics, LEU: leukotriene , MMAS: Morisky Medication Adherence Scale, MPR:
medication possession ratio, NA: not available, PDC: proportion of days covered, RCT: Randomized Clinical Trial, SAAC: short acting a ticholinergics, SABA: short acting beta agonists, SAL:
salmeterol, TIO: tiotropium, XAN: xanthines.
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108 J.F.M. van Boven et al.Toy et al. analyzed the relationship between adherence,
daily dosing regimen, healthcare resource utilization (inpa-
tient, outpatient and ED visits) and costs. A large adminis-
trative claims database was used to identify COPD patients
(N Z 55,076). Adherence was measured as proportion of
days covered (PDC) over a 1-year period after initiation of
treatment. Results of a multivariate regression model
showed that a 5% increase in adherence would lead to a 2.6%
reduction in hospital visits and a 1.8% reduction in ED visits.
The other study, from Butler et al. aimed, using a
retrospective longitudinal design, to determine the asso-
ciation between adherence to medication and total (non-
disease specific) emergency department visits. They espe-
cially focused on long-term benefits of adherence. Data on
the use of prescription drugs were obtained from a national
Medical Expenditure Panel Survey (MEPS), but specific
medication was not specified. The non-adherence ratio was
calculated by dividing the number of non-adherent days by
the total days in a year.
While no significant short-term effects of adherence on
number of ED visits were observed, long-term effects of
non-adherence were detected.
Other clinical outcomes that were associated with
adherence included pulmonary symptoms (cough, phlegm
and dyspnea), decrease in lung function and provocative
concentration causing a 20% fall in FEV1 (PC20) during ste-
roid treatment [18,23]. However, these results were based
on studies with either a small population (Dompeling et al.)
or were measured in patients using nebulized therapy only
(Turner et al.) making results less generalizable.
Mortality
Only two studies investigated the association between
adherence and mortality. The study by Vestbo et al. [22]
showed that good adherence was not only associated with
decreased risk of severe exacerbations but also with a
decreased risk of death. Using different threshold levels to
define adherence, revealed a hierarchic association be-
tween rate of adherence and mortality: the lower the
adherence, the higher the mortality. However, authors
noted that patients with poor adherence may have had
more comorbidities with multiple medications affecting
adherence and prognosis, which may have biased the re-
sults. Remarkable was that the effect of adherence was as
strong in the placebo group as in the group treated with
medication, which is referred to as the ‘healthy adherer
effect’: adherence to therapy is an indicator for an overall
healthier lifestyle. In contrast, the other study, by Turner
et al. [23] found no significant differences in mortality
between adherent and non-adherent patients. However,
the lack of significance may be, just as for the other clinical
outcomes, due to the use of a nonconventional threshold
for adherence.
Costs
Three studies were identified describing the association
between adherence and costs [17,19,20].
The Simoni-Wastila et al. study showed that adherent
patients had higher costs for prescription medicationcompared with non-adherent patients. However, these
costs were offset by lower inpatient- and outpatient costs
resulting in lower total spending for adherent compared to
non-adherent patients.
The second study was the administrative database anal-
ysis of Toy et al. In addition to the influence of a 5% increase
of adherence on healthcare utilization they also calculated
related costs. To obtain a cost estimate reflecting the na-
tional population, patient data were weighted. Increasing
PDC with 5% resulted in lower expenditures for inpatient-
and ER visits. In contrast, costs for outpatient visits would
slightly increase, resulting in an overall net cost reduction.
The retrospective claims analysis from Halpern et al.
compared adherence and outcomes between COPD patients
initiating tiotropium (n Z 1561) or salmeterol/fluticasone
(n Z 2976) therapy using claims data from a large national
US health plan. Follow-up was at least one year with a
maximum follow-up of 1.5 years.
Adherence was defined as a medication possession ratio
(MPR) 0.80. Pharmacy costs were higher in adherent pa-
tients compared with non-adherent patients. In contrast, in
inpatient stay costs were lower in adherent patients as
compared with non-adherent patients.
All studies found, not surprisingly, that medication costs
were higher in adherent patients compared with non-
adherent patients. In contrast, inpatient stay (hospitaliza-
tion) costs were lower in adherent patients compared to
non-adherent patients in all studies. In the study of Halpern
et al. [20] adherence was associated with lower respiratory
related medical costs but overall healthcare costs in
adherent patients where higher compared with non-
adherent patients, which may be explained by a possible
‘healthcare seeking behavior’ of adherent patients. The
two remaining studies found lower total healthcare costs in
adherent patients [17,19]. Regarding all costs, standard
deviations were considerable, indicating large between
patient variation.Quality of life
Four studies assessed the impact of non-adherence on
health related quality of life (HRQoL). The instruments
used to measure HRQoL differed between studies. Two
studies [25,26] used the St. George’s Respiratory Ques-
tionnaire (SGRQ), which is COPD specific, widely applied in
the field of COPD and is considered a suitable tool to assess
quality of life. [27] The Corden et al. study was a small
(n Z 82) 4-week prospective cohort study in patients using
nebulized therapy. 74% were COPD patients and most pa-
tients were using bronchodilators. Patients’ adherence was
measured using data loggers attached to the nebulizer.
Poor compliance was defined as taking less than 70% of the
prescribed treatment. The second study, from Takemura
et al. was a cross-sectional analysis of 88 COPD patients and
assessed factors related to inhalation therapy adherence
and its correlation with quality of life. Adherence was
measured using a self-reported questionnaire where pa-
tients with a score of 4 (on a 5-point Likert scale) were
considered adherent.
Both studies showed that the SGRQ total, symptoms and
impact scores were negatively correlated with adherence,
Adherence to COPD medication and outcomes 109although the association with symptoms and impact scores
did not achieve statistical significance in the Corden et al.
study, which may be due to the relatively small study pop-
ulation [26]. On the other hand, note that the Takemura
et al. study applied a method of self-reported adherence
that may have biased patient adherence in a positive di-
rection and thereby have resulted in an overestimation [25].
In contrast, another study found an association be-
tween adherence and lower HRQoL as measured with the
EQ-5D [28].
The Agh et al. study was an observational cross sectional
study in 170 COPD outpatients from Hungary. Adherence
was measured with the Morisky Medication Adherence Scale
(MMAS) and patients scoring 3 (out of 4) were considered
adherent.
The EQ-5D is a general instrument and thereforemay not be
sensitive to COPD specific HRQoL; furthermore better quality
of life may be considered a trigger for non-adherence. In
addition, patient’s decision regarding adherence was sug-
gested a personal trade-off betweenbenefits of treatment and
the associated negative effects (lifestyle changes, side
effects).
Other HRQoL-tools used included the Sickness Impact
Profile (SIP), the Profile of Mood States (POMS), and the
Recent Life Changes Questionnaire (RLCQ); for the latter a
significant association was found between non-adherence
and a more disrupted home and family life [23]. This pro-
spective cohort study in patient using nebulized therapy (by
Turner et al.) demonstrated that an unstable environment
may have a negative effect on treatment adherence,
especially when the medication regimen requires adjust-
ments in daily living.
Productivity
Regarding the association between adherence and produc-
tivity only one study was identified [16]. This 1-year retro-
spective cross sectional analysis of administrative healthcare
claims by Carls et al. aimed to estimate the impact of medi-
cation adherence on absenteeism and short-term disability.
A population of 5417 (absenteeism) respectively 20,985
(short-term disability) patients with asthma/COPD was
assessed. Employees were classified adherent as the pro-
portion of days covered was 80% and during hospital days
patients were assumed to be adherent. Results were cor-
rected for switching between medication and relevant con-
founders. However, no clear distinction was made between
asthma and COPD patients in particular. Adherent patients
were significantly fewerdays absent fromworkandhad fewer
days of short-term disability. In their discussion the authors
estimated the potential annual savings of adherent em-
ployees compared with non-adherent employees around
$1714 per employee. Short-term absenteeism accounted for
$178 to $833 per employee per year (Table 2).
Discussion
Main findings
This review revealed a clear association between adher-
ence to COPD medication and both clinical and economicoutcomes. Evidence from the twelve studies included,
showed increased hospitalizations, mortality, quality of life
and loss of productivity among non-adherent patients.
Several key elements were uncovered regarding the direc-
tion of this association reported in adherence studies
measuring clinical symptoms. Adherence alone is not al-
ways sufficient to obtain improved clinical outcomes, but
rather the combination of continuous use (persistence) in
combination with high adherence [17]. Furthermore, the
omission to include long-term effects of non-adherence
may cause an underestimation of the actual costs and ef-
fects of non-adherence [21].
Vestbo et al. [22] provides evidence for an association
between high adherence and significantly decreased mor-
tality in patients with moderate to severe COPD. Note that
this evidence is based on a selective trial population, so
generalizing these results towards the complete COPD pop-
ulation may be tendentious [29]. Three recent studies
described the association between adherence and costs and
showed some clear patterns. Not surprisingly, costs of
medication will increase when adherence is increased.
However, both medical (inpatient) and total costs are likely
to decrease in adherent patients as reported by Toy et al. and
Simoni-Wastila et al. [17,19] Halpern et al. did not observe
effects on total costs, which was explained by a higher
healthcare seeking behavior of adherent patients [20].
Regarding quality of life, studies showed contrasting
effects by reporting either small positive or small negative
effects of improved adherence [23,25,26,28]. It was sug-
gested that better quality of life may be considered a
trigger for non-adherence [23,28]. Good adherence re-
quires some rigorous adjustments in patients’ daily life and
this may have a negative reflection on their perceived
quality of life, outweighing for instance the benefits of
somewhat less frequent exacerbations [28].
The association between adherence and work produc-
tivity was least described, but evidence indicated that
adherence was significantly associated with reduced days
off work, putting a high burden on societal expenses [16].
Further research on work productivity is recommended, as
better understanding of this topic would be of great value
in order to reduce non-adherence related costs in the
working age population [30].
An overall interesting theory some studies refer to is the
so called ‘healthy adherer effect’ [17,22]. The healthy
adherer effect assumes that therapy adherence is a surro-
gate marker for an overall healthy behavior [22]. This raises
the question whether better clinical and economic out-
comes can be solely explained and established by the
improvement of patients’ medication adherence, or rather
by an extensive change in patients’ behavior (lifestyle,
adherence to co-medication).Limitations and considerations
Though the association between adherence and outcomes
is rather clear, evidence is mainly based on observational
studies not well-suited to measure any causal effect of non-
adherence. On the other hand, compared to clinical trials,
observational studies provide long-term ‘real world’ evi-
dence as seen in daily practice, thereby providing
Table 2 Outcomes associated with adherence to COPD therapy.
Study Outcome specification Absolute outcomes Relative outcomes Significance
Non-adherent Adherent p-value
Clinical outcomes
Dompeling [18] r
Pulmonary symptoms NR 0.57 0.036
Change in FEV1 NR 0.6 n.s.
Change in PC20 NR 0.72 0.031
Turner [23]
Change in FEV1 0.034 0.04 NR n.s.
Days hospitalized 4.2 3.8 NR n.s.
Matuszewski [24]
Hospitalizations NR n.s.
Vestbo [22] Rate ratio
Hospitalizations 0.27 0.15 0.58 (0.44e0.73) <0.001
Butler [21] Hazard rate
ED visits NR 1011 n.s.
Toy [19] Difference (%)
ED visits 802 817 15 (1.8%) NR
Hospitalizations 1275 1243 33 (2.6%) NR
Hospital days 5906 5720 186 (3.1%) NR
Outpatient visits 16,981 17,010 29 (þ0.2%) NR
Simoni-Wastila [17] Adjusted RR
Hospitalizations 1.13 0.88 0.90 (0.87e0.93) <0.05
Mortality
Turner [23]
Percentage died 22.6% 23.7% NR n.s.
Vestbo [22] Hazard rate
Percentage died 26.4% 11.3% 0.40 (0.35e0.46) <0.001
Economic outcomes
Halpern [20] Cost ratio
Healthcare costs NR 1.469 (1.13e1.91) <0.01
Medical costs NR 0.629 (0.43e0.91) <0.05
Inpatient costs NR 0.466 (0.30e0.72) <0.01
Toy [19] Difference (%)
ED costs $412.658 $405.248 $7.410 (1.8%) NR
Hospital costs $11.635.099 $11.338.501 $296.598 (2.6%) NR
Outpatient costs $1.867.863 $1.871.082 $3.219 (þ0.2%) NR
Simoni-Wastila [17] Marginal effects
Inpatient costs $19.594 $14.061 $4.609 <0.001
Outpatient costs $12.664 $11.450 $606 <0.001
Drug costs $7.546 $9.190 $1.654 <0.001
Quality of life
Turner [23]
POMS total score 26.3 27.7 NR n.s.
SIP total score 16.3 16.5 NR n.s.
RLCQ home score 1.22 1.04 NR 0.04
Corden [26] r
SGRQ symptoms NR 2201 0.054
SGRQ impact NR 2213 0.053
SGRQ total NR 2477 0.03
Agh [28]
EQ-5D 0.62 0.50 NR 0.001
Takemura [25] r
SGRQ symptoms NR 0.43 0.002
SGRQ impact NR 0.35 0.011
SGRQ activities NR 0.17 n.s.
SGRQ total NR 0.35 0.023
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Table 2 (continued )
Study Outcome specification Absolute outcomes Relative outcomes Significance
Non-adherent Adherent p-value
Productivity
Carls [16] Difference
Absent days NR 7.1 (3.0  11.7) <0.05
Short-term disability days NR 3.7 (1.7  5.8) <0.05
NR: not reported; n.s.: not significant.
Adherence to COPD medication and outcomes 111important added value regarding the generalizability of
results among the overall COPD population.
To include all the evidence, no stringent inclusion
criteria related to the design of the studies were applied.
As a result a wide variety of studies was included, making it
difficult to combine quantitative results and synthesize
evidence through a meta-analysis. In this review, unpub-
lished and non-English studies were excluded; although
non-English works have been shown to result in limited
added value [14] this may be considered a limitation of our
literature search.
Regarding measurement of adherence, most studies
used prescription refill data from pharmacy or administra-
tive databases. Although prescription records provide a
relatively cheap and fast platform to obtain adherence
data, a prescription may not guarantee patients have
actually taken their medication, or when taken, used their
inhalers correctly. Mishandling of inhalers is common and
also associated with reduced disease control [31]. Some
studies used self-reported adherence but these were
considered to be prone to patient information bias in a
positive direction [32].
Furthermore, although well accepted in current litera-
ture, the most often used threshold of 80% of the propor-
tion of days covered remains rather arbitrary. Electronic
pills count or measuring blood serum levels may provide a
more accurate way of measuring adherence but are
expensive and invasive. Database studies often lacked in-
formation on disease severity. To overcome this limitation,
two studies recommend to use proxies for disease severity
such as use of oxygen or the number of prior hospitaliza-
tions [17,19].
It is recommended to assess the effect of different levels
of adherence on medication efficacy in prospective clinical
trials. It would be of great value to report the effect of non-
adherence on the effectiveness of the therapy, as in ‘real
life’ adherence is much lower than in trials performed in a
highly controlled setting [4,33]. These measurements
would also provide some evidence on the minimum effec-
tive dosing regimen needed to still obtain a high benefit
from COPD medication. To fully understand the long-term
clinical and economic effects of non-adherence, the time
patients are followed should be extended to a period more
than one year. Longitudinal disease control should be
measured using validated questionnaires like the SGRQ
[27], Clinical COPD Questionnaire (CCQ) [34] or COPD
Assessment Test (CAT) [35]. One of the problems may be
the difficulty of avoiding that patients are aware that their
adherence behavior is being monitored.Implications for future research, policy and
practice
Interventions that improve adherence (behavior) are rec-
ommended, focusing not only on adherence to medication
but on the total ‘package’ of modifying patients’ adherence
behavior as a whole.
Adherence is dependent on the patient, treatment and
societal factors [5e7]. Strategies to improve adherence
have been described [36] and include increasing patients’
knowledge about self-management, enhancing healthcare
providers’ communication skills and counseling.
There is some evidence that interventions can increase
patients’ adherence to COPD medication [25], but in gen-
eral studies assessing both the effect on adherence and the
effect on outcomes are limited [37]. Further studies are
recommended to identify the most (cost)effective in-
terventions to improve medication adherence in patients
with COPD. Latest studies show that interventions need to
focus on both adherence as well as continued use (persis-
tence) to fulfill the maximal potential of improved health
and economic outcomes [17].
Regarding the association between non-adherence and
overall worsened outcomes, targeting on specific patients
in need of interventions will be facilitated by actively
searching for patients with suboptimal adherence to COPD
therapy. These ‘targeted’ interventions are expected to be
highly cost-effective compared with interventions using a
‘one-size-fits-all’ principle.
Conclusions
This review showed a clear association between adherence
to COPD medication and clinical and economic outcomes,
making non-adherent patients a priority for cost-effective
interventions.Acknowledgements
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